141 related articles for article (PubMed ID: 12659890)
41. Meloxicam.
Fleischmann R; Iqbal I; Slobodin G
Expert Opin Pharmacother; 2002 Oct; 3(10):1501-12. PubMed ID: 12387696
[TBL] [Abstract][Full Text] [Related]
42. Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application.
Gupta SK; Bansal P; Bhardwaj RK; Jaiswal J; Velpandian T
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):105-11. PubMed ID: 11867967
[TBL] [Abstract][Full Text] [Related]
43. Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family.
García-Vicuña R; Díaz-González F; González-Alvaro I; del Pozo MA; Mollinedo F; Cabañas C; González-Amaro R; Sánchez-Madrid F
Arthritis Rheum; 1997 Jan; 40(1):143-53. PubMed ID: 9008610
[TBL] [Abstract][Full Text] [Related]
44. Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium(III) oxicam complexes. In vivo evaluation of anti-inflammatory and gastric damaging activities.
Tamasi G; Bernini C; Corbini G; Owens NF; Messori L; Scaletti F; Massai L; Giudice PL; Cini R
J Inorg Biochem; 2014 May; 134():25-35. PubMed ID: 24518539
[TBL] [Abstract][Full Text] [Related]
45. Optimization of photocatalytic degradation of meloxicam using titanium dioxide nanoparticles: application to pharmaceutical wastewater analysis, treatment, and cleaning validation.
Nadim AH; Al-Ghobashy MA; Nebsen M; Shehata MA
Environ Sci Pollut Res Int; 2015 Oct; 22(20):15516-25. PubMed ID: 26006070
[TBL] [Abstract][Full Text] [Related]
46. Cathodic adsorptive stripping square-wave voltammetry of the anti-inflammatory drug meloxicam.
Radi AE; Ghoneim M; Beltagi A
Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1257-60. PubMed ID: 11605650
[TBL] [Abstract][Full Text] [Related]
47. Density functional calculations on meloxicam-beta-cyclodextrin inclusion complexes.
Snor W; Liedl E; Weiss-Greiler P; Viernstein H; Wolschann P
Int J Pharm; 2009 Nov; 381(2):146-52. PubMed ID: 19446616
[TBL] [Abstract][Full Text] [Related]
48. Oxicam structure in non-steroidal anti-inflammatory drugs is essential to exhibit Akt-mediated neuroprotection against 1-methyl-4-phenyl pyridinium-induced cytotoxicity.
Tasaki Y; Yamamoto J; Omura T; Noda T; Kamiyama N; Yoshida K; Satomi M; Sakaguchi T; Asari M; Ohkubo T; Shimizu K; Matsubara K
Eur J Pharmacol; 2012 Feb; 676(1-3):57-63. PubMed ID: 22182582
[TBL] [Abstract][Full Text] [Related]
49. Spectrophotometric determination of piroxicam and tenoxicam in pharmaceutical formulations using alizarin.
Amin AS
J Pharm Biomed Anal; 2002 Jul; 29(4):729-36. PubMed ID: 12093502
[TBL] [Abstract][Full Text] [Related]
50. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam.
Obach RS; Kalgutkar AS; Ryder TF; Walker GS
Chem Res Toxicol; 2008 Sep; 21(9):1890-9. PubMed ID: 18707140
[TBL] [Abstract][Full Text] [Related]
51. Oxicam-induced photosensitivity. Patch and photopatch testing studies with tenoxicam and piroxicam photoproducts in normal subjects and in piroxicam-droxicam photosensitive patients.
Serrano G; Fortea JM; Latasa JM; SanMartin O; Bonillo J; Miranda MA
J Am Acad Dermatol; 1992 Apr; 26(4):545-8. PubMed ID: 1597539
[TBL] [Abstract][Full Text] [Related]
52. Polarographic behaviour of Aceclofenac, Tenoxicam and Droxicam in a methanol-water mixture.
Acuña JA; Vázquez MD; Tascón ML; Sánchez-Batanero P
J Pharm Biomed Anal; 2004 Sep; 36(1):157-62. PubMed ID: 15351060
[TBL] [Abstract][Full Text] [Related]
53. Non-pigmenting cutaneous-mucosal fixed drug eruption due to piroxicam.
Montoro J; Díaz M; Genís C; Lozano A; Bertomeu F
Allergol Immunopathol (Madr); 2003; 31(1):53-5. PubMed ID: 12573211
[TBL] [Abstract][Full Text] [Related]
54. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.
Xu S; Rouzer CA; Marnett LJ
IUBMB Life; 2014 Dec; 66(12):803-11. PubMed ID: 25537198
[TBL] [Abstract][Full Text] [Related]
55. Modulating Properties of Piroxicam, Meloxicam and Oxicam Analogues against Macrophage-Associated Chemokines in Colorectal Cancer.
Lewandowska P; Szczuka I; Bednarz-Misa I; Szczęśniak-Sięga BM; Neubauer K; Mierzchała-Pasierb M; Zawadzki M; Witkiewicz W; Krzystek-Korpacka M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885960
[TBL] [Abstract][Full Text] [Related]
56. Stability-indicating chromatographic methods for the determination of some oxicams.
Taha EA; Salama NN; Abdel Fattah Lel-S
J AOAC Int; 2004; 87(2):366-73. PubMed ID: 15164829
[TBL] [Abstract][Full Text] [Related]
57. Characterization and evaluation of tenoxicam coprecipitates.
el-Gazayerly ON
Drug Dev Ind Pharm; 2000 Sep; 26(9):925-30. PubMed ID: 10914316
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of interaction of the non-steroidal antiinflammatory drugs meloxicam and nimesulide with serum albumin.
Seedher N; Bhatia S
J Pharm Biomed Anal; 2005 Sep; 39(1-2):257-62. PubMed ID: 16085140
[TBL] [Abstract][Full Text] [Related]
59. Analysis of meloxicam by high-performance liquid chromatography with cloud-point extraction.
Zhang H; Choi HK
Anal Bioanal Chem; 2008 Nov; 392(5):947-53. PubMed ID: 18751683
[TBL] [Abstract][Full Text] [Related]
60. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450.
Zhao J; Leemann T; Dayer P
Life Sci; 1992; 51(8):575-81. PubMed ID: 1640808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
